Composition for treating hyperlipidemia comprising oxyntomodulin derivative

Abstract

The present invention relates to a composition for preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis, comprising an oxyntomodulin derivative as an active ingredient. The oxyntomodulin derivative has a high ability to activate GLP-1 receptor and glucagon receptor compared to native oxyntomodulin and has the effects of reducing the blood total cholesterol, low-density cholesterol and triglyceride levels that were increased by high-fat diet, and increasing high-density cholesterol levels and the high-density cholesterol/low-density cholesterol ratio. Thus, the oxyntomodulin derivative can be effectively used for the treatment of hyperlipidemia and related diseases.

1 . A composition for preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis, comprising an oxyntomodulin derivative as an active ingredient. 
     
     
         2 . The composition according to  claim 1 , wherein the oxyntomodulin derivative has an amino acid sequence selected from the group consisting of SEQ ID NOs: 2 to 34. 
     
     
         3 . The composition according to  claim 1 , wherein the oxyntomodulin derivative is in the form of a conjugate linked to one selected from the group consisting of an immunoglobulin fragment, an antibody, elastin, albumin and fibronectin. 
     
     
         4 . The composition according to  claim 3 , wherein the conjugate is a conjugate in which the oxyntomodulin derivative having the amino acid sequence selected from the group consisting of SEQ ID NOs: 2 to 34 is linked to an immunoglobulin Fc region via a non-peptidyl polymer. 
     
     
         5 . The composition according to  claim 4 , wherein the non-peptidyl polymer is selected from the group consisting of polyethylene glycol, polypropylene glycol, an ethylene glycol/propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, polysaccharides, dextran, polyvinyl ethyl ether, PLA (polylactic acid), PLGA (polylactic-glycolic acid), lipid polymers, chitins, hyaluronic acid, and combinations thereof. 
     
     
         6 . The composition according to  claim 4 , wherein one end of the non-peptidyl polymer and the other are linked to an amine group or a thiol group of the immunoglobulin Fc region and the oxyntomodulin derivative, respectively. 
     
     
         7 . The composition according to  claim 1 , further comprising a pharmaceutical agent showing preventive or therapeutic effects against hyperlipidemia, fatty liver disease or arteriosclerosis. 
     
     
         8 . The composition according to  claim 1 , wherein the fatty liver disease is non-alcoholic fatty liver disease, alcoholic fatty liver disease, nutritional fatty liver disease, starvation fatty liver disease, obesity fatty liver disease, diabetic fatty liver disease or steatohepatitis. 
     
     
         9 . The composition according to  claim 8 , wherein the non-alcoholic fatty liver disease results from hyperlipidemia, diabetes or obesity. 
     
     
         10 . The composition according to  claim 8 , wherein the non-alcoholic fatty liver disease is selected from the group consisting of simple steatosis, non-alcoholic steatohepatitis, liver fibrosis and liver cirrhosis. 
     
     
         11 . A method for preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis, comprising a step of administering an oxyntomodulin derivative to a subject. 
     
     
         12 . Use of an oxyntomodulin derivative in preparation of a medicament for preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis.